Current Management and Progress in Radiotherapy for Small Cell Lung Cancer

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Small cell lung cancer (SCLC) management relies heavily on radiotherapy (RT) and chemotherapy.
• Concurrent chemoradiotherapy (CRT) with etoposide and platinum is standard for limited-stage SCLC.
• Prophylactic cranial irradiation (PCI) is standard for responding limited-stage SCLC patients.

Purpose of the Study:

• To review the current role and future directions of radiotherapy in SCLC management.
• To summarize recent advancements in systemic therapies, including immunotherapy.
• To discuss evolving radiation techniques and their potential impact on SCLC treatment.

Main Methods:

• This is a narrative review summarizing existing literature and clinical trial data.
• The review focuses on established and emerging radiotherapy and chemotherapy regimens.
• Current treatment standards and future therapeutic strategies are discussed.

Main Results:

• Concurrent chemoradiotherapy (CRT) is the standard for limited-stage SCLC.
• Immunotherapy addition to chemotherapy is recommended for extensive-stage SCLC.
• Novel radiation techniques like hippocampal avoidance and stereotactic radiosurgery (SRS) show promise.

Conclusions:

• Radiotherapy remains a cornerstone in SCLC management, with evolving techniques.
• Integration of immunotherapies has significantly altered the SCLC treatment paradigm.
• Future directions involve refining radiation delivery and combining novel systemic agents.